Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro-and anti-angiogenic profiles

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 18, 2014, Pages 1854-1859

  Alahakoon, Thushari I ^a   Zhang, Weiyi ^a   Trudinger, Brian J ^a   Lee, Vincent W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Angiogenic factors; Fetal growth restriction; Preeclampsia

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; ENDOGLIN; PLACENTAL GROWTH FACTOR; PROTEIN SKDR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FETAL DOPPLER; FETUS; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PREECLAMPSIA; PREGNANCY DISORDER; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; UMBILICAL ARTERY; BLOOD; FETAL GROWTH RETARDATION; NEWBORN; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84903960547     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.880882     Document Type: Article

References (31)

1. Sibai BM. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008; 52:805-6.
2. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
3. Chaiworapongsa T, Romero R, Gotsch F, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41-52.
4. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009;30:S38-42.
5. Smith GCS, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009;21:111-16.
6. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005;48:372-86.
7. Andraweera PH, Dekker G, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012;18:436-57.
8. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007;112:51-7.
9. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83.
10. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
11. Arduini D, Rizzo G, Boccolini MR, et al. Functional assessment of uteroplacental and fetal circulations by means of color Doppler ultrasonography. J Ultrasound Med 1990;9:249-53.
12. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40.
13. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. [Erratum appears in Nat Med 2006;12:862]. Nat Med 2006;12:642-9.
14. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. [Erratum appears in N Engl J Med 2006;355:1840]. N Engl J Med 2006; 355:992-1005.
15. Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normo-tensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895-903.
16. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
17. Savvidou MD, Yu CK, Harland LC, et al. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006;195:1668-73.
18. Stepan H, Kramer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007;92:2831-4.
19. Todros T, Sciarrone A, Piccoli E, et al. Umbilical Doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. Obstet Gynecol 1999;93: 499-503.
20. Shen BQ, Lee DY, Gerber HP, et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998;273:29979-85.
21. Chaiworapongsa T, Romero R, Tarca AL, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol 2010;202: 550.e1-10.
22. Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 2007;20:495-507.
23. Rana S, Schnettler W, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189-201.
24. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-38.
25. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7; discussion 1547-50.
26. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61:932-42.
27. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-70.
28. Bamfo JEAK, Kametas NA, Chambers JB, Nicolaides KH. Maternal cardiac function in normotensive and pre-eclamptic intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 32:682-6.
29. Redman CW, Denson KW, Beilin LJ, et al. Factor-VIII consumption in pre-eclampsia. Lancet 1977;2:1249-52.
30. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195:40-9.
31. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-50.